WHAT IS CLAIMED IS:

1. A compound having the formula



or a pharmaceutically acceptable salt thereof.

2. The compound of Claim 1 that is the sodium salt of N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]propanamide.

3. A pharmaceutical composition comprising in a unit dose thereof a therapeutically effective amount in total of at least one compound selected from N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]propanamide and pharmaceutically acceptable salts thereof, the composition being orally deliverable and substantially free of water and having means for inhibiting degradation of said at least one compound to celecoxib prior to oral administration.

4. The composition of Claim 3 wherein said at least one compound is the sodium salt of N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-propanamide.

5. The composition of Claim 3 wherein said therapeutically effective amount is equivalent to about 10 mg to about 1000 mg celecoxib.

6. The composition of Claim 3 wherein said therapeutically effective amount is equivalent to about 50 mg to about 400 mg celecoxib.

7. The composition of Claim 3 wherein the degradation inhibiting means comprises means for substantially preventing exposure of the composition to water.

8. The composition of Claim 7 wherein the exposure preventing means comprises a

sealed and substantially water-impermeable package or container.

9. The composition of Claim 7 wherein the exposure preventing means comprises a substantially water-impermeable coating.

10. The composition of Claim 3 wherein the degradation inhibiting means comprises a formulation of the composition having substantially no amount of any excipient that tends to promote such degradation when in intimate contact with said at least one compound.

11. The composition of Claim 5 that comprises an excipient that tends to promote degradation of said at least one compound to celecoxib, wherein the degradation inhibiting means comprises a formulation of the composition having a barrier layer between said excipient and said at least one compound.

12. An article of manufacture comprising a substantially water-impermeable package, having contained therein a single unit dose of an orally deliverable pharmaceutical composition that is substantially free of water and comprises a therapeutically effective amount in total of at least one compound selected from N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]-sulfonyl]propanamide and pharmaceutically acceptable salts thereof.

13. The article of Claim 12 wherein said at least one compound is the sodium salt of N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-propanamide.

14. The article of Claim 12 wherein the composition is in a form of a powder and the package is a sealed container suitable when opened for addition of an aqueous vehicle wherein the composition can be dissolved.

15. The article of Claim 12 wherein the composition is in a form of a tablet and the package is a foil pack or blister pack.

16. A method of treatment or prophylaxis of a COX-2 mediated condition in a subject, the method comprising administering a therapeutically effective amount in total of at least one compound selected from the group consisting of N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]propanamide and pharmaceutically acceptable salts thereof to the subject.

17. The method of Claim 16 wherein said at least one compound is the sodium salt of N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-propanamide.

18. A method of treating or preventing a COX-2 mediated disorder in a subject, the method comprising (a) dissolving, in a pharmaceutically acceptable aqueous vehicle, at least one unit dose of a pharmaceutical composition that is substantially free of water and comprises a therapeutically effective amount in total of at least one compound selected from N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]propanamide and pharmaceutically acceptable salts thereof, to form a solution, and (b) orally administering the solution to the subject before substantial precipitation of insoluble matter occurs in the solution.

19. The method of Claim 18 wherein said at least one compound is the sodium salt of N-[[4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]sulfonyl]-propanamide.